Press Release


National Cancer Institute Prostate Cancer Screening Study Indicates QTscan Has Equal or Better Sensitivity Than MRI 

Novato, CA – July 28, 2022 – QT Imaging, Inc., a medical device company focused on the development and clinical adoption of novel products for body imaging, today announced results of a National Cancer Institute study comparing the QTscan with 7-Tesla MRI for prostate cancer screening. In an initial series of 10 patients, blinded QT Imaging interpretation demonstrated equal or better sensitivity for detection of cancer compared with multi-parametric 7-Tesla MRI. The study was done in collaboration with the Urologic Oncology Branch, Center for Interventional Oncology National Cancer Institute, Bethesda, MD and the Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD.

On blinded sector-based analysis, QT’s low frequency transmitted ultrasound volography™ had a sensitivity of 85.7% and specificity of 93.9%, while mpMRI had a sensitivity of 65.3% and specificity of 96.6%. These results demonstrate that QT’s imaging technology has significant potential as a low-cost, high resolution imaging modality for prostate cancer.

From the Abstract: While multiparametric MRI (mpMRI) and targeted biopsy have improved detection of high-risk prostate cancer (PCa) over traditional B-mode gray scale ultrasound, use of mpMRI in the diagnostic pathway for PCa remains limited due to variability in image acquisition and interpretation, accessibility, and cost. Low frequency transmitted ultrasound volography, previously shown to have high sensitivity for the diagnosis of breast cancer, provides 360-degree submillimeter-resolution imaging for tissue characterization and cancer detection even in the presence of bone and air, and with limited view tomographic data. In this study, we sought to validate this technique for detection of prostate cancer by imaging ex vivo whole prostate specimens after radical prostatectomy, comparing lesion detection and visualization with low frequency transmitted ultrasound volography with mpMRI, and correlating imaging findings with wholemount histopathology.

Prostate specimens were collected from fifty-three patients undergoing Robot Assisted Radical Prostatectomy (RARP) for biopsy-confirmed PCa from February 2021 to February 2022. Thirteen of fifty-three prostate specimens had scanned and annotated histopathology slides and mpMRI scans; three were excluded for a history of androgen deprivation therapy or radiation. Of the remaining ten, the median age at surgery was 60 years [IQR 58.3-67.5] and median PSA was 6.85 ng/mL [IQR 5.78-8.73]. Six patients had Gleason Grade Group (GG) two cancer on RARP, one had GG 3, two had GG 4, and 1 had GG 5.

“These results demonstrate the clinical value of QT’s low frequency transmitted sound volography as a high-resolution imaging modality. We are encouraged by the continued high performance of QT imaging, especially in general anatomic and body imaging,” said John Klock, MD, CEO and CMO at QT Imaging.

These results were reported at three scientific meetings:
American Urological Association meeting Sept. 2021
Engineering and Urology Society 35th Annual Meeting, “2022 Best Abstract Award”, J. Enders
SPIE Medical Imaging, Feb. 2022

About QT Imaging, Inc.
QT Imaging™ is a privately held company engaged in the research, development, and commercialization of an innovative automated imaging system producing high-resolution transmission ultrasound images. The company has received FDA 510(K) clearance for its QT Imaging Breast Scanner, and the National Institutes of Health (NIH) has awarded over $15 million in funding to support QT Imaging research. The company’s clinical trials have been conducted at prestigious institutions in the US and Europe.

The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient’s breast. The device is not intended to be used as a replacement for screening mammography.